Evercore ISI raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $126 from $101 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals reports Q4 revenue $148.93M, consensus $141.81M
- Mirum Pharmaceuticals sees FY26 global net product sales $630M-$650M
- Mirum Pharmaceuticals falls -16.5%
- Mirum Pharmaceuticals price target raised to $130 from $123 at Morgan Stanley
- Mirum Pharmaceuticals price target raised to $117 from $115 at TD Cowen